Aclarion, Inc. announced an 85% year-over-year increase in scan volumes for Q3 2026, contributing to a 117% growth for the first nine months of the year. The company highlighted the publication of supportive clinical data in the European Spine Journal and the expansion of its CLARITY trial to eleven sites with updated enrollment criteria to speed recruitment. With $14.2 million in cash, Aclarion expects to fund its 300-patient CLARITY trial through the second half of 2027. These developments support Aclarion's commercial growth and reimbursement efforts in the UK and US, with an initial trial readout anticipated by year-end.
Aclarion's Q3 2026 update shows strong scan volume growth and clinical progress. For readers following the health sector, here is Pluang's market snapshot as of Oct 20, 2026 17:41 WIB: 80 of 150 US health stocks rose, 62 fell. Notable movers include BKD at USD 10.08 (+2.23%), SNY at USD 40.45 (+2.22%), and ELAN at USD 22.99 (-2.13%).
CNH Industrial has agreed to sell a 70% stake in its construction equipment business to Kobelco Construction Machinery, forming a joint venture valued at $1 billion. This move allows CNH to focus on becoming a pure-play agriculture equipment and tech...
US President Donald Trump defended his family's cryptocurrency business, World Liberty Financial, stating he has no involvement in its operations and cannot stop his sons from running it while he is in office. The company faces scrutiny over a $500 m...
Bitcoin briefly fell below $74,000 on Nov. 8 as over $1 billion in leveraged crypto positions were forcibly closed ahead of upcoming U.S. inflation data. It later recovered above $75,000. Over five U.S. trading sessions ending Nov. 6, Bitcoin ETFs sa...
XRP has sharply declined against Bitcoin, losing nearly 8% of its value over the past week amid a broader cryptocurrency market downturn. The coin dropped 4.9% in the last 24 hours and is currently priced around $1.10. This decline is more severe tha...
Dapirolizumab pegol (DZP), an investigational biologic for systemic lupus erythematosus (SLE), demonstrated greater treatment response rates compared to placebo when combined with standard care in the Phase 3 PHOENYCS GO trial. Using a novel Treatmen...
